Search results
Results from the WOW.Com Content Network
NovoRapid is produced in Saccharomyces cerevisiae by recombinant DNA technology. [11] A faster acting version of aspart insulin, known as fast-aspart (Fiasp) insulin, is associated with more efficient control of post-prandial rise in blood glucose, without increasing the risks of hypoglycemia and glycemic variability. [31] [32] [33]
Novo Nordisk created "aspart" and marketed it as NovoLog/NovoRapid (UK-CAN) as a rapid-acting insulin analogue. It was created through recombinant DNA technology so that the amino acid, B28, which is normally proline , is substituted with an aspartic acid residue.
Regular insulin, also known as neutral insulin and soluble insulin, is a type of short-acting medical insulin. [2] It is used to treat type 1 diabetes, type 2 diabetes, gestational diabetes, and complications of diabetes such as diabetic ketoacidosis and hyperosmolar hyperglycemic states. [5]
As a medication, insulin is any pharmaceutical preparation of the protein hormone insulin that is used to treat high blood glucose. [6] Such conditions include type 1 diabetes, type 2 diabetes, gestational diabetes, and complications of diabetes such as diabetic ketoacidosis and hyperosmolar hyperglycemic states. [6]
NPH insulin is cloudy and has an onset of 1–3 hours. Its peak is 6–8 hours and its duration is up to 24 hours. [9]It has an intermediate duration of action, meaning longer than that of regular and rapid-acting insulin, and shorter than long acting insulins (ultralente, glargine or detemir).
Insulin is a peptide hormone containing two chains cross-linked by disulfide bridges. Insulin (/ ˈ ɪ n. sj ʊ. l ɪ n /, [5] [6] from Latin insula, 'island') is a peptide hormone produced by beta cells of the pancreatic islets encoded in humans by the insulin (INS) gene.
Former logo. Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, [3] with production facilities in nine countries and affiliates or offices in five.
Long-term studies like the UK Prospective Diabetes Study (UKPDS) and the Diabetes control and complications trial (DCCT) showed that intensive insulin therapy achieved blood glucose levels closer to non-diabetic people and that this was associated with reduced frequency and severity of blood vessel damage.